Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases

ABSTRACT

Inflammatory and immunological skin diseases such as psoriasis, systemic sclerosis, dermatomyositis and atopic dermatitis, whose abnormal skin manifestations not only affected life quality but also caused social discrimination, have been wildly concerned. Complex variables such as hereditary predisposition, racial differences, age and gender can influence the prevalence and therapeutic options. The population of patients with unsatisfactory curative effects under current therapies is growing, it’s advisable to seek novel and advanced therapies that are less likely to cause systemic damage. Mesenchymal stem cells (MSCs) have been proven with therapeutic benefits in tissue regeneration, self-renewal and differentiation abilities when treating refractory skin disorders in preclinical and clinical studies. Here we highlighted the immune modulation and inflammation suppression of MSCs in skin diseases, summarized current studies, research progress and related clinical trials, hoping to strengthen the confidence of promising MSCs therapy in future clinical application.

KEYWORDS:

• MSC therapy
• psoriasis
• systemic sclerosis
• dermatomyositis
• atopic dermatitis

View correction statement:

Correction

Acknowledgments

This study was supported by grants from the Key science and technology R&D project of Zhejiang Province (2021C03077).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Authors’ contributions

CH collected references, summarized clinical trials and wrote the manuscript. SC drew the graphical summaries. HC reviewed and checked the article. The authors have approved the final manuscript.

Additional information

Funding

The work was supported by the the Key science and technology R&D project of Zhejiang Province [2021C03077].